Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has renewed two agreements to continue leasing certain property and assets from controlling shareholder Kelun Pharmaceutical for the three years ending Dec. 31, 2027, a Jan. 28 bourse filing said.
The leased properties in Chengdu, China, are being used by the company for its daily operations, such as for R&D activities, and as a storage house, office space, and staff housing solution.
The equipment comprises around 1,074 pieces of equipment including manufacturing and laboratory equipment and instruments.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。